Atara Biotherapeutics Inc is a biopharmaceutical company specializing in allogeneic T-cell immunotherapy. The company harnesses the natural biology of T cells to develop transformative therapies for patients with cancer, autoimmune conditions, and severe viral infections.

Atara Biotherapeutics

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Atara Biotherapeutics, Inc.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  

With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.  

Kleiner Perkins

Celgene

DAG Ventures

Domain Associates

EcoR1 Capital

Alexandria

Amgen Ventures

Today Atara announced the publication of the pivotal ALLELE tab-cel® study data in patients with relapsed or refractory Epstein-Barr virus (#EBV) positive post-transplant lymphoproliferative disease (#PTLD) in The Lancet Oncology, representing the first Phase 3 results published for an #allogeneic #Tcell therapy. 

➡Press release: https://bit.ly/4bkXbT1 

It was a pleasure highlighting the latest developments and potential of Atara's #allogeneic #CART programs for hematological malignancies and autoimmune diseases at #JPM24. https://bit.ly/3vxNksE

Next week, our CEO Pascal Touchon is heading to San Francisco to share Atara's latest pipeline progress & key development milestones at the J.P. Morgan Annual Healthcare Conference on Thursday, January 11 at 9:45 a.m. PT: https://bit.ly/3H8hXrd 

At this year's American Society of Hematology Annual Meeting, Atara will present positive preclinical data on ATA3431, our investigational next-generation #allogeneic CD20/CD19-targeted #CAR #EBV T-cell therapy for the treatment of B-cell malignancies. For more: https://bit.ly/3GA8b0O #ASH23  

COM:ATARABIO

Atara Biotherapeutics Inc

Last Close

10.10

08/11 21:00

Market Cap

44.24M

Beta: -

Volume Today

154.07K

Avg: -

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

competitor of

Metrics